PDS Biotechnology Granted FDA Fast Track Designation For Lead Candidate PDS0101
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the
77 Biggest Movers From Yesterday
Gainers
TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.
PDS Biotech Announces Presentation Of Efficacy And Safety Data From VERSATILE-002 Phase 2 Clinical Trial In Recurrent Or Metastatic Head And Neck Cancer At ASCO 2022
PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
Preliminary data from first 19 patients treated with
PDS Biotechnology Q1 EPS $(0.32) Misses $(0.22) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 128.57 percent decrease over losses of $(0.14) per share
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Earnings Outlook For PDS Biotechnology
PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement.
Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.24.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.